I’m part of a presentation at COPD9 that’s focusing on how policy drives practice in COPD. What I’m looking at specifically is how insurance companies are reducing our choices on the meds we are offered by offering only one in a class of meds; for instance, offering only Symbicort or Advair but not both. If you’ve had this experience, please take this survey:
-- SURVEY NO LONGER ACTIVE --
I’ll report the results of the survey at COPD9 in Chicago.